natgillin/translations-raw huggingface dataset:
History of previous serious allergic drug reaction of any type, especially cutaneous reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme or patients with known hypersensitivity to sulfonamides (see sections 4.4 and 4.8). 
Anamneza kakršnekoli resne alergijske reakcije na zdravila, zlasti kožnih reakcij, npr. StevensJohnsonovega sindroma, toksične epidermalne nekrolize, multiformnega eritema ali bolniki z znano preobčutljivostjo na sulfonamide (glejte poglavji 4.4. in 4.8).
Treatment of post-operative pain following coronary artery bypass graft (CABG) surgery (see sections 4.8 and 5.1). 
Zdravljenje pooperacijske bolečine po CABG (operativna vstavitev presadka koronarnega obvoda) (glejte poglavji 4.8 in 5.1).
However, in the repeated dose toxicity studies in dogs and rats, the systemic exposures to valdecoxib (the active metabolite of parecoxib) were approximately 0.8-fold the systemic exposure in elderly human subjects at the maximum recommended therapeutic dose of 80 mg daily. 
Vendar je bila sistemska izpostavljenost valdekoksibu (aktivnemu presnovku parekoksiba) v študijah toksičnosti ponavljajočih se odmerkov pri psih in podganah približno 0,8-kratnik sistemske izpostavljenosti pri starejših osebah pri največjem priporočenem terapevtskem odmerku 80 mg na dan.
A significantly (p=0.033) greater incidence of events in the cardiovascular/thromboembolic category was detected in the parecoxib/valdecoxib treatment group (2.0%) compared to the placebo/placebo treatment group (0.5%). 
Znatno večjo pojavnost (p = 0,033) dogodkov v kategoriji kardiovaskularnih/trombemboličnih obolenj so odkrili pri skupini, ki je bila zdravljena s parekoksibom/valdekoksibom (2,0 %), v primerjavi s skupino, ki je prejemala placebo/placebo
However, the reported rate of serious skin events appears to be greater for valdecoxib (the active metabolite of parecoxib) as compared to other COX-2 selective inhibitors. 
Toda, kot kaže, je opisani delež resnih kožnih reakcij večji pri valdekoksibu (aktivnem presnovku parekoksiba) kot pri drugih selektivnih zaviralcih COX-2.
The IV line must be adequately flushed prior to and after Dynastat injection with a solution of known compatibility (see section 6.6). 
Pred injiciranjem zdravila Dynastat in po njem je treba intravensko pot temeljito sprati z znano kompatibilno raztopino (glejte poglavje 6.6).
This medicine does not require any special storage conditions prior to reconstitution. 
Za shranjevanje zdravila pred rekonstitucijo niso potrebna posebna navodila.
In those patients where the same IV line is to be used to inject another medicinal product, the line must be adequately flushed prior to and after Dynastat injection with a solution of known compatibility. 
Če se pri bolniku uporablja ista intravenska pot za injiciranje drugih zdravil, je treba pot pred injiciranjem zdravila Dynastat in po njem ustrezno sprati z raztopino, za katero je znano, da je kompatibilna.
In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of NSAIDs, including Dynastat should be considered. 
Pri ženskah, ki imajo težave z zanositvijo ali pri katerih potekajo preiskave zaradi neplodnosti, je smiselno razmisliti o prekinitvi zdravljenja z nesteroidnimi protivnetnimi zdravili, vključno z zdravilom Dynastat.
Circulatory collapse, congestive heart failure, tachycardia 
Cirkulatorni kolaps, kongestivno srčno popuščanje, tahikardija
Use of water for injection is not recommended, as the resulting solution is not isotonic. 
Uporaba vode za injekcije ni priporočljiva, ker nastala raztopina ni izotonična.
▪ NSAIDs, including Dynastat, may make it more difficult to become pregnant. 
• Zaradi nesteroidnih protivnetnih zdravil, vključno z zdravilom Dynastat, je morda težje zanositi.
Plasma clearance (CLp) for valdecoxib is about 6 l/hr. 
Plazemski očistek (CLp) valdekoksiba je približno 6 l/uro.
The NSAIDs class is also associated with increased GI complications when coadministered with glucocorticoids, selective serotonin reuptake inhibitors, other antiplatelet drugs, other NSAIDs or patients ingesting alcohol. 
Ta razred NSAID je povezan s pogostejšimi gastrointestinalnimi zapleti tudi pri sočasni uporabi z glukokortikoidi, selektivnimi zaviralci ponovnega privzema serotonina, drugimi antiagregacijskimi zdravili, drugimi NSAID ali pri bolnikih, ki uživajo alkohol.
Coadministration of valdecoxib and lithium produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone. 
Sočasna uporaba valdekoksiba in litija je povzročila pomembno zmanjšanje serumskega (25 %) in ledvičnega očistka (30 %) litija, tako da se je serumska izpostavljenost v primerjavi s samim litijem povečala za 34 %.
Dissolve the powder completely using a gentle swirling motion and inspect the reconstituted product before use. 
Prašek popolnoma raztopite tako, da vialo previdno obračate; pred uporabo rekonstituirano raztopino preglejte.
For storage conditions of the reconstituted medicinal product see section 6.3. 
Za pogoje shranjevanja po rekonstituciji zdravila glejte poglavje 6.3.
Because renal elimination of valdecoxib is not important to its disposition, no changes in valdecoxib clearance were found even in patients with severe renal impairment or in patients undergoing dialysis (see section 4.2). 
Ker izločanje valdekoksiba skozi ledvice ni pomembno za njegovo odstranjevanje, sprememb očistka valdekoksiba niso ugotovili niti pri bolnikih s hudo ledvično okvaro ali na dializi (glejte poglavje 4.2).
Also contains disodium hydrogen phosphate, phosphoric acid and sodium hydroxide. 
Vsebuje tudi natrijev hidrogenfosfat, fosforjevo kislino in natrijev hidroksid.
In humans, studies demonstrated that valdecoxib metabolism is predominantly mediated via CYP3A4 and 2C9 isozymes. 
Študije so pokazale, da presnova valdekoksiba pri ljudeh poteka pretežno s pomočjo izoencimov CYP3A4 in 2C9.
There is further increase in the risk of gastrointestinal adverse effects (gastrointestinal ulceration or other gastrointestinal complications), when parecoxib is taken concomitantly with acetylsalicylic acid (even at low doses). 
Tveganje za neželene učinke v prebavilih (razjeda v prebavilih ali drugi gastrointestinalni zapleti), se še dodatno poveča, kadar se parekoksib uporablja sočasno z acetilsalicilno kislino (celo pri majhnih odmerkih).
Precipitation may occur when Dynastat is combined in solution with other medicinal products and therefore Dynastat must not be mixed with any other medicinal product, either during reconstitution or injection. 
Če zdravilo Dynastat kombiniramo v raztopini z drugimi zdravili, lahko pride do precipitacije, zato zdravila Dynastat ne smemo mešati z drugimi zdravili niti med rekonstitucijo niti med injiciranjem.
Dynastat should not be injected into an IV line delivering any other medicinal product. 
Zdravila Dynastat ne smemo injicirati v intravensko pot, v katero apliciramo druga zdravila.
The most serious reactions occur uncommonly to rarely, and include cardiovascular events such as myocardial infarction and severe hypotension, as well as hypersensitivity events such as anaphylaxis, angioedema and severe skin reactions. 
Večina resnih neželenih učinkov se pojavi občasno do redko in vključujejo srčnožilne dogodke, npr. miokardni infarkt in hudo hipotenzijo, ter preobčutljivostne reakcije, kot so anafilaktične reakcije, angioedem in hude kožne reakcije.
Dynastat should be used with caution in patients with moderate hepatic impairment (Child-Pugh score 7-9) (see section 4.2). 
Zdravilo Dynastat je treba uporabljati previdno pri bolnikih z zmerno okvaro jeter (ocena od 7 do 9 po Child-Pughu) (glejte poglavje 4.2).
Dynastat is available in packs containing 10 vials. 
Zdravilo Dynastat je na voljo v naslednjem pakiranju: škatla z 10 vialami.
Therefore, caution should be observed when administering Dynastat with medicinal products known to be substrates of CYP2C19 (e.g. phenytoin, diazepam, or imipramine). 
Zato je potrebna previdnost med uporabo zdravila Dynastat z zdravili, za katera je znano, da so substrati CYP2C19 (npr. fenitoin, diazepam ali imipramin).
Dynastat may mask fever and other signs of inflammation (see section 5.1). 
Zdravilo Dynastat lahko prikrije zvišano telesno temperaturo in druge znake vnetja (glejte poglavje 5.1).
Marketing Authorisation Holder: Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium 
Imetnik dovoljenja za promet: Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgija
Adverse Drug Reaction Frequency Very Common 
Pogostnost neželenih učinkov Zelo pogosti
Reconstitution solvents This medicinal product must not be mixed with other medicinal products. 
Zdravila ne smemo mešati z drugimi zdravili.
In two pharmacokinetic interaction studies in rheumatoid arthritis patients receiving a stable weekly methotrexate dose (5-20 mg/week, as a single oral or intramuscular dose), orally administered valdecoxib (10 mg twice daily or 40 mg twice daily) had little or no effect on the steady-state plasma concentrations of methotrexate. 
V dveh farmakokinetičnih študijah o medsebojnem delovanju pri bolnikih z revmatoidnim artritisom, ki so enkrat na teden dobivali stabilen odmerek metotreksata (5-20 mg/teden kot enkratni peroralni ali intramuskularni odmerek), je peroralno dan valdekoksib (10 mg dvakrat na dan ali 40 mg dvakrat na dan) malo ali pa sploh ni vplival na koncentracijo metotreksata v plazmi v stanju dinamičnega ravnovesja.
Effects of other medicinal products on the pharmacokinetics of parecoxib (or its active metabolite valdecoxib) 
Vpliv drugih zdravil na farmakokinetiko parekoksiba (ali njegovega aktivnega presnovka valdekoksiba)
The reconstituted product is isotonic. 
Rekonstituirano zdravilo je izotonično.
A hydroxylated metabolite of valdecoxib (via the CYP pathway) has been identified in human plasma that is active as a COX-2 inhibitor. 
V človeški plazmi je bil ugotovljen hidroksilirani presnovek valdekoksiba (po poti CYP), ki deluje kot zaviralec COX-2.
The mean (SD) duration of treatment was 4.1 (0.4) days for parecoxib and 4.2 (0.5) days for placebo, the range was 4-7 days for parecoxib and 4-9 days for placebo. 
Povprečno (standardni odklon [SD - Standard Deviation]) trajanje zdravljenja je bilo 4,1 (0,4) dneva pri parekoksibu in 4,2 (0,5) dneva pri placebu, z razponom 4-7 dni pri parekoksibu in 4-9 dni pri placebu.
The metabolism of valdecoxib may increase when coadministered with enzyme inducers such as rifampicin, phenytoin, carbamazepine or dexamethasone. 
Presnova valdekoksiba se lahko poveča pri sočasni uporabi induktorjev encimov, kakršni so rifampicin, fenitoin, karbamazepin ali deksametazon.
Dynastat may be coadministered with opioid analgesics. 
Zdravilo Dynastat se lahko uporablja sočasno z opioidnimi analgetiki.
The most common adverse reaction for Dynastat is nausea. 
Najbolj pogost neželeni učinek zdravila Dynastat je navzea.
There is limited clinical experience with Dynastat treatment beyond three days (see section 5.1). 
Kliničnih izkušenj z več kot tridnevno uporabo zdravila Dynastat je malo (glejte poglavje 5.1).
Hypertension (aggravated), orthostatic hypotension Respiratory, thoracic and mediastinal disorders Respiratory insufficiency 
Hipertenzija (poslabšanje), ortostatska hipotenzija Bolezni dihal, prsnega koša in mediastinalnega prostora Respiratorna insuficienca
There are no adequate data from the use of parecoxib in pregnant women or during labour. 
O uporabi parekoksiba pri nosečnicah ali med porodom ni dovolj podatkov.
Severe hepatic impairment (serum albumin <25 g/l or Child-Pugh score 10). 
Huda okvara jeter (albumin v serumu < 25 g/l ali ocena ≥ 10 po Child-Pughu).
SOLVENT AMPOULE LABEL : 2 ml 
NALEPKA NA AMPULI Z VEHIKLOM: 2 ml
Infections and infestations Pharyngitis, alveolar osteitis (dry socket) 
Infekcije in parazitske bolezni Faringitis, suhi alveolitis (»suha jamica«)
Parecoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. 
Parekoksib je treba ukiniti ob prvem pojavu kožnega izpuščaja, lezij na sluznicah ali kakršnegakoli drugega znaka preobčutljivosti.
Within each frequency grouping, adverse reactions are listed using MedDRA terminology and presented in order of decreasing seriousness. 
V razvrstitvah pogostnosti so neželeni učinki, upoštevajoč MedDRA terminologijo, navedeni po padajoči resnosti.
This interaction should be given consideration in patients receiving parecoxib concomitantly with ACE-inhibitors, angiotensin II antagonists, beta-blockers and diuretics. 
To medsebojno delovanje je treba upoštevati pri bolnikih, ki parekoksib prejemajo sočasno z zaviralci ACE, antagonisti angiotenzina II, antagonisti adrenergičnih receptorjev beta in diuretiki.
Therefore, caution should be observed when coadministering Dynastat and medicinal products that are predominantly metabolised by CYP2D6 and which have narrow therapeutic margins (e.g. flecainide, propafenone, metoprolol). 
Zato je potrebna previdnost med sočasno uporabo zdravila Dynastat in zdravil, ki se presnavljajo pretežno s CYP2D6 in imajo ozko terapevtsko območje (npr. flekainid, propafenon, metoprolol).
Parecoxib should be discontinued at the first sign of hypersensitivity. 
Zdravljenje s parekoksibom je treba prekiniti ob prvih znakih preobčutljivosti.
Parecoxib is rapidly hydrolysed to the active metabolite valdecoxib. 
Parekoksib se hitro hidrolizira v aktivni presnovek valdekoksib.
The use of Dynastat, as with any medicinal product known to inhibit cyclooxygenase/prostaglandin synthesis, is not recommended in women attempting to conceive (see sections 4.3, 5.1 and 5.3). 
Uporaba zdravila Dynastat, tako kot drugih zdravil, za katera je znano, da zavirajo sintezo ciklooksigenaze/prostaglandinov, pri ženskah, ki načrtujejo nosečnost, ni priporočljiva (glejte poglavja 4.3, 5.1 in 5.3).
- If you have further questions, ask your doctor or nurse. 
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali medicinsko sestro.
Following coronary artery bypass graft surgery, patients administered Dynastat have a higher risk of adverse reactions such as: cardiovascular/thromboembolic events (including myocardial infarction, stroke/TIA, pulmonary embolus, and deep vein thrombosis; see sections 4.3 and 5.1), deep surgical infections, and sternal wound healing complications. 
Po obvodni operaciji koronarnih arterij bolnike, ki dobijo zdravilo Dynastat, bolj ogrožajo neželeni učinki, kot so: kardiovaskularni/tromboembolični dogodki (vključujoč miokardni infarkt, kap/TIA, pljučno embolijo in globoko vensko trombozo; glejte poglavji 4.3 in 5.1), globoke kirurške okužbe in zapleti na sternalni rani.
In animals, administration of prostaglandin synthesis inhibitors, including parecoxib, has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality (see sections 5.1 and 5.3). 
Pri živalih se je pokazalo, da uporaba zaviralcev sinteze prostagladinov, vključno s parekoksibom, zveča izgube zarodkov pred in po implantaciji in embrionalno-fetalno smrtnost (glejte poglavji 5.1 in 5.3).
If you are given more Dynastat than you should you may experience side-effects that have been reported with recommended doses. 
Če ste dobili večji odmerek zdravila Dynastat, kot bi smeli, se pri vas lahko pojavijo neželeni učinki, opisani pri uporabi običajnih odmerkov.
Gastroduodenal ulceration, gastrooesophageal reflux disease, dry mouth, gastrointestinal sounds abnormal 
Gastroduodenalne razjede, gastroezofagealni refluks, suha usta, nenormalni prebavni zvoki
As the cardiovascular risk of COX-2 specific inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. 
Kardiovaskularno tveganje zaradi specifičnih zaviralcev COX-2 se pri večjih odmerkih in daljši izpostavljenosti lahko poveča, zato mora biti zdravljenje čim krajše in z najmanjšim učinkovitim dnevnim odmerkom.
However caution is advised when methotrexate is administered concurrently with NSAIDs, because NSAID administration may result in increased plasma levels of methotrexate. 
Kljub temu je priporočljiva previdnost pri sočasni uporabi metotreksata z nesteroidnimi protivnetnimi zdravili, ker lahko dajanje le-teh privede do zvišanih koncentracij metotreksata v plazmi.
Dynastat is supplied as a sterile, single unit-of-use vial that is packaged with a 2 ml ampoule with a fill volume of 2 ml sodium chloride 9 mg/ml (0.9%) solution (see below for various pack sizes and configurations) 
Zdravilo Dynastat je na voljo v obliki sterilne viale za enkratno uporabo, skupaj z 2 ml ampulo s polnitveno prostornino 2 ml raztopine natrijevega klorida 9 mg/ml (0,9 %) (glejte spodaj za različna pakiranja).
Diuresis or alkalisation of urine may not be useful due to high protein binding of valdecoxib. 
Diureza ali alkalizacija urina sta vprašljiva ukrepa, ker je valdekoksib v veliki meri vezan na beljakovine.
Three of the six cardiovascular thromboembolic events in the placebo/valdecoxib treatment group occurred during the placebo treatment period; these patients did not receive valdecoxib. 
Trije od šestih kardioavskularnih/trombemboličnih dogodkov pri skupini, ki je prejemala placebo/valdekoksib, so se pojavili med prejemanjem placeba.
Coadministration of NSAIDs and ciclosporin or tacrolimus has been suggested to increase the nephrotoxic effect of ciclosporin and tacrolimus because of NSAID effects on renal prostaglandins. 
Sočasna uporaba nesteroidnih protivnetnih zdravil in ciklosporina ali takrolimusa naj bi povečala nefrotoksični učinek ciklosporina in takrolimusa zaradi učinka nesteroidnih protivnetnih zdravil na ledvične prostaglandine.
Anticoagulant therapy should be monitored, particularly during the first few days after initiating Dynastat therapy in patients receiving warfarin or other anticoagulants, since these patients have an increased risk of bleeding complications. 
Pri bolnikih, ki prejemajo varfarin ali druge antikoagulante, je treba nadzirati antikoagulantno zdravljenje, zlasti v prvih nekaj dneh po uvedbi zdravila Dynastat, saj imajo ti bolniki povečano tveganje za hemoragične zaplete.
These decreases were not considered clinically important since Cmax of valdecoxib is comparable after IM and IV parecoxib administration. 
Tega zmanjšanja niso ocenili za klinično pomembnega, ker je Cmax valdekoksiba po i.m.
COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. 
COX-2 je izooblika encima, za katero je dokazano, da jo inducirajo provnetni dražljaji; domnevno je ta izooblika odgovorna za sintezo prostanoidnih mediatorjev bolečine, vnetja in zvišane telesne temperature.
These results indicate that although valdecoxib is not metabolised by CYP2C19, it may be an inhibitor of this isoenzyme. 
To kaže, da valdekoksib lahko zavira CYP2C19, čeprav se ne presnavlja s pomočjo tega izoencima.
In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors or Angiotensin-II antagonists, may result in further deterioration of renal function, including possible acute renal failure. 
Pri starejših bolnikih s hipovolemijo (vključno s tistimi, ki se zdravijo z diuretiki), ali z zmanjšanim delovanjem ledvic, lahko sočasna uporaba nesteroidnih protivnetnih zdravil, vključno s selektivnimi zaviralci COX-2, z zaviralci ACE ali antagonisti angiotenzina II povzroči nadaljnje poslabšanje ledvične funkcije, vključno z akutno odpovedjo ledvic.
Inflammatory bowel disease. 
Vnetna črevesna bolezen.
Following IV or IM injection, parecoxib is rapidly converted to valdecoxib, the pharmacologically active substance, by enzymatic hydrolysis in the liver. 
Po intravenski ali intramuskularni injekciji se parekoksib z encimsko hidrolizo v jetrih hitro spremeni v farmakološko aktivno učinkovino valdekoksib.
Parecoxib is suspected to cause serious birth defects when administered during the last trimester of pregnancy because as with other medicinal products known to inhibit prostaglandin, it may cause premature closure of the ductus arteriosus or uterine inertia (see sections 4.3, 5.1 and 5.3). 
Obstaja sum, da lahko parekoksib v zadnjem trimesečju nosečnosti povzroči resne okvare ploda, ker lahko - tako kot druga zdravila, ki zavirajo prostaglandine - povzroči prezgodnje zaprtje arterioznega duktusa ali inertnost maternice (glejte poglavja 4.3, 5.1 in 5.3).
There is limited experience in other types of surgery, for example gastrointestinal or urological surgery (see section 5.1). 
Izkušnje pri drugih vrstah operacij, npr. gastrointestinalnih in uroloških, so omejene (glejte poglavje 5.1).
Gastrointestinal studies 
Študije trombocitov
5 + 5 pack: contains 5 powder vials and 5 solvent ampoules. 
Pakiranje 5 + 5: vsebuje 5 vial praška in 5 ampul vehikla.
There is no clinical experience in patients with severe hepatic impairment (Child-Pugh score 10), therefore its use is contraindicated in these patients (see sections 4.3 and 5.2). 
Kliničnih izkušenj pri bolnikih s hudo okvaro jeter (ocena  10 po Child-Pughu) ni, zato je zdravilo pri njih kontraindicirano (glejte poglavji 4.3 in 5.2).
Plasma exposure of omeprazole (CYP 2C19 substrate) 40 mg once daily was increased by 46% following administration of valdecoxib 40 mg twice daily for 7 days, while the plasma exposure to valdecoxib was unaffected. 
Plazemska izpostavljenost omeprazolu (substratu CYP2C19) v odmerku 40 mg enkrat na dan se je po 7-dnevni uporabi valdekoksiba 40 mg dvakrat na dan povečala za 46 %, plazemska izpostavljenost valdekoksibu pa se ob tem ni spremenila.
Average Cmax of parecoxib after IM dosing was lower compared to bolus IV dosing, which is attributed to slower extravascular absorption after IM administration. 
Povprečna Cmax parekoksiba je bila po intramuskularni uporabi manjša kot po bolusni intravenski uporabi, kar je treba pripisati počasnejši zunajžilni absorpciji po intramuskularni aplikaciji.
Thus, 24 hours should be considered the maximum shelf life of the reconstituted product. 
Torej je maksimalni rok uporabnosti rekonstituirane raztopine 24 ur.
Blood pressure should be monitored closely during the initiation of therapy with parecoxib and throughout the course of therapy. 
Med uvedbo in ves čas zdravljenja s parekoksibom je treba natančno nadzirati krvni tlak.
Valdecoxib is eliminated via hepatic metabolism with less than 5% unchanged valdecoxib recovered in the urine. 
Valdekoksib se izloča s presnovo v jetrih; manj kot 5 % valdekoksiba se nespremenjenega izloči z urinom.
In clinical trials, the daily requirement for PRN opioids was significantly reduced when coadministered with parecoxib. 
V kliničnih preskušanjih se je dnevna potreba po opioidih PP (PP - po potrebi) pomembno zmanjšala, če so bili uporabljeni sočasno s parekoksibom.
Nine prespecified adverse event categories were evaluated (cardiovascular thromboembolic events, pericarditis, new onset or exacerbation of congestive heart failure, renal failure/dysfunction, upper GI ulcer complications, major non-GI bleeds, infections, non-infectious pulmonary complications, and death). 
Ocenjevali so devet vnaprej določenih kategorij neželenih dogodkov (kardiovaskularni/trombembolični dogodki, perikarditis, ponovni pojav ali poslabšanje kongestivnega srčnega popuščanja, odpoved/poslabšano delovanje ledvic, zapleti z razjedami v zgornjih prebavilih, močne krvavitve, ki ne izvirajo iz prebavil, infekcije, neinfektivni pulmonalni zapleti in smrt).
As with other medicinal products known to inhibit prostaglandin synthesis, fluid retention and oedema have been observed in some patients taking parecoxib. 
Tako kot pri drugih zdravilih, ki zavirajo sintezo prostaglandinov, so tudi pri bolnikih, ki so jemali parekoksib, opazili zastajanje tekočine in edeme.
The solvent is contained in colourless neutral glass ampoules (2 ml). 
Vehikel je pakiran v brezbarvne ampule (2 ml) iz nevtralnega stekla.